Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
195 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Dengue Fever - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dengue Fever - Pipeline Review, H2 2016, provides an overview of the Dengue Fever (Infectious Disease) pipeline landscape. Dengue is a mosquito borne infectious disease caused by the dengue virus. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from nose, gums, or under skin. It can also become dengue shock syndrome, which causes massive bleeding and shock. Treatment includes use of analgesics, fluid replacement therapy and healthy life style. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dengue Fever - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dengue Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Dengue Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Dengue Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 5, 32 and 16 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 2, 6, 10 and 15 molecules, respectively. Dengue Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Dengue Fever (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Dengue Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Dengue Fever (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Dengue Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Dengue Fever (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Dengue Fever (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Dengue Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 5 Dengue Fever Overview 6 Therapeutics Development 7 Dengue Fever - Therapeutics under Development by Companies 9 Dengue Fever - Therapeutics under Investigation by Universities/Institutes 12 Dengue Fever - Pipeline Products Glance 14 Dengue Fever - Products under Development by Companies 17 Dengue Fever - Products under Investigation by Universities/Institutes 20 Dengue Fever - Companies Involved in Therapeutics Development 22 Dengue Fever - Therapeutics Assessment 59 Drug Profiles 68 Dengue Fever - Dormant Projects 164 Dengue Fever - Discontinued Products 170 Dengue Fever - Product Development Milestones 171 Appendix 184
List of Tables
Number of Products under Development for Dengue Fever, H2 2016 17 Number of Products under Development for Dengue Fever - Comparative Analysis, H2 2016 18 Number of Products under Development by Companies, H2 2016 19 Number of Products under Development by Companies, H2 2016 (Contd..1) 20 Number of Products under Development by Companies, H2 2016 (Contd..2) 21 Number of Products under Investigation by Universities/Institutes, H2 2016 23 Comparative Analysis by Late Stage Development, H2 2016 24 Comparative Analysis by Clinical Stage Development, H2 2016 25 Comparative Analysis by Early Stage Development, H2 2016 26 Products under Development by Companies, H2 2016 27 Products under Development by Companies, H2 2016 (Contd..1) 28 Products under Development by Companies, H2 2016 (Contd..2) 29 Products under Investigation by Universities/Institutes, H2 2016 30 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 31 Dengue Fever - Pipeline by Abivax SA, H2 2016 32 Dengue Fever - Pipeline by Agilvax Inc, H2 2016 33 Dengue Fever - Pipeline by Altravax Inc, H2 2016 34 Dengue Fever - Pipeline by Biological Mimetics Inc, H2 2016 35 Dengue Fever - Pipeline by Bioneer Corp, H2 2016 36 Dengue Fever - Pipeline by Biotron Ltd, H2 2016 37 Dengue Fever - Pipeline by Codagenix Inc, H2 2016 38 Dengue Fever - Pipeline by Emergent BioSolutions Inc, H2 2016 39 Dengue Fever - Pipeline by Ennaid Therapeutics LLC, H2 2016 40 Dengue Fever - Pipeline by GeneSegues Inc, H2 2016 41 Dengue Fever - Pipeline by GlaxoSmithKline Plc, H2 2016 42 Dengue Fever - Pipeline by Globavir Biosciences Inc, H2 2016 43 Dengue Fever - Pipeline by Hawaii Biotech Inc, H2 2016 44 Dengue Fever - Pipeline by HSRx Group, H2 2016 45 Dengue Fever - Pipeline by Humabs BioMed SA, H2 2016 46 Dengue Fever - Pipeline by Immunotope Inc, H2 2016 47 Dengue Fever - Pipeline by Inovio Pharmaceuticals Inc, H2 2016 48 Dengue Fever - Pipeline by Johnson & Johnson, H2 2016 49 Dengue Fever - Pipeline by Kineta Inc, H2 2016 50 Dengue Fever - Pipeline by Merck & Co Inc, H2 2016 51 Dengue Fever - Pipeline by Molplex Ltd, H2 2016 52 Dengue Fever - Pipeline by NanoViricides Inc, H2 2016 53 Dengue Fever - Pipeline by Novartis AG, H2 2016 54 Dengue Fever - Pipeline by NovaTarg Therapeutics Inc, H2 2016 55 Dengue Fever - Pipeline by Panacea Biotec Ltd, H2 2016 56 Dengue Fever - Pipeline by Plex Pharmaceuticals Inc, H2 2016 57 Dengue Fever - Pipeline by ProtInhi BV, H2 2016 58 Dengue Fever - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 59 Dengue Fever - Pipeline by Sarepta Therapeutics Inc, H2 2016 60 Dengue Fever - Pipeline by SIGA Technologies Inc, H2 2016 61 Dengue Fever - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2016 62 Dengue Fever - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 63 Dengue Fever - Pipeline by TechnoVax Inc, H2 2016 64 Dengue Fever - Pipeline by Themis Bioscience GmbH, H2 2016 65 Dengue Fever - Pipeline by VaxInnate Corp, H2 2016 66 Dengue Fever - Pipeline by Visterra Inc, H2 2016 67 Dengue Fever - Pipeline by VLP Therapeutics LLC, H2 2016 68 Assessment by Monotherapy Products, H2 2016 69 Number of Products by Stage and Target, H2 2016 71 Number of Products by Stage and Mechanism of Action, H2 2016 73 Number of Products by Stage and Route of Administration, H2 2016 75 Number of Products by Stage and Molecule Type, H2 2016 77 Dengue Fever - Dormant Projects, H2 2016 174 Dengue Fever - Dormant Projects (Contd..1), H2 2016 175 Dengue Fever - Dormant Projects (Contd..2), H2 2016 176 Dengue Fever - Dormant Projects (Contd..3), H2 2016 177 Dengue Fever - Dormant Projects (Contd..4), H2 2016 178 Dengue Fever - Dormant Projects (Contd..5), H2 2016 179 Dengue Fever - Discontinued Products, H2 2016 180
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.